11 research outputs found
"Miljön Àr viktigt, dÀr vistas barn hela tiden" - En studie om förskolans inlÀrningsmiljö
Studien har till syfte att ta reda pÄ hur fem olika förskollÀrare tÀnker kring betydelsen av inomhusmiljön som frÀmjande för barns lÀrande och utveckling. FrÄgestÀllningarna har besvarats med hjÀlp av en kvalitativ metod. Vi har utfört semistrukturerade intervjuer med fem förskollÀrare frÄn fyra olika förskolor.
Verksamhetens synsÀtt pÄ barns inlÀrning har betydelse för vilka möjligheter som skapas för barnen att lÀra och utvecklas i sin förskolemiljö. Studien kommer benÀmna teorier utifrÄn det utvecklingspsykologiska forskningsfÀltet dÄ dessa teorier har pÄverkat samhÀllets barnsyn. Studiens slutsatser visade pÄ att miljön en viktig resurs i verksamheten. Den bör, enligt förskollÀrarna, vara förÀnderlig tillsammans med barnen. Det Àr Àven fördelaktigt om miljön erbjuder olika aktiviteter som gynnar det individuella barnets utveckling och lÀrande. FörskollÀrarna fick vid intervjun beskriva sin idealiska arbetsmiljö, vilket gav oss mÄnga intressanta svar. Deras olika perspektiv kan utveckla nya tankar och idéer till vÄr framtida yrkesroll som förskollÀrare
The utility of isotope-coded protein labeling for prioritization of proteins found in ovarian cancer patient urine
Urine offers a number of attractive features as a sample type for
biomarker discovery, including noninvasive sampling, quantity and
availability, stability, and a narrow dynamic range. In this study
we report the first application of isotope coded protein labeling
(ICPL), coupled with in-solution isoelectric fractionation and LC-MALDI-TOF/TOF,
to examine and prioritize urinary proteins from ovarian cancer patients.
Following the definition of stringent exclusion criteria a total of
579 proteins were identified with 43% providing quantitation data.
Protein abundance changes were validated for selected proteins by
ESI-Qq-TOF MS, following which Western blot and immunohistochemical
analysis by tissue microarray was used to explore the biological relevance
of the proteins identified. Several established markers (e.g., HE4,
osteopontin) were identified at increased levels in ovarian cancer
patient urine, validating the approach used; we also identified a
number of potential marker candidates (e.g., phosphatidylethanolamine
binding protein 1, cell-adhesion molecule 1) previously unreported
in the context of ovarian cancer. We conclude that the ICPL strategy
for identification and relative quantitation of urine proteins is
an appropriate tool for biomarker discovery studies, and can be applied
for the selection of potential biomarker candidates for further characterization
The utility of isotope-coded protein labeling for prioritization of proteins found in ovarian cancer patient urine
Urine offers a number of attractive features as a sample type for
biomarker discovery, including noninvasive sampling, quantity and
availability, stability, and a narrow dynamic range. In this study
we report the first application of isotope coded protein labeling
(ICPL), coupled with in-solution isoelectric fractionation and LC-MALDI-TOF/TOF,
to examine and prioritize urinary proteins from ovarian cancer patients.
Following the definition of stringent exclusion criteria a total of
579 proteins were identified with 43% providing quantitation data.
Protein abundance changes were validated for selected proteins by
ESI-Qq-TOF MS, following which Western blot and immunohistochemical
analysis by tissue microarray was used to explore the biological relevance
of the proteins identified. Several established markers (e.g., HE4,
osteopontin) were identified at increased levels in ovarian cancer
patient urine, validating the approach used; we also identified a
number of potential marker candidates (e.g., phosphatidylethanolamine
binding protein 1, cell-adhesion molecule 1) previously unreported
in the context of ovarian cancer. We conclude that the ICPL strategy
for identification and relative quantitation of urine proteins is
an appropriate tool for biomarker discovery studies, and can be applied
for the selection of potential biomarker candidates for further characterization
The utility of isotope-coded protein labeling for prioritization of proteins found in ovarian cancer patient urine
Urine offers a number of attractive features as a sample type for
biomarker discovery, including noninvasive sampling, quantity and
availability, stability, and a narrow dynamic range. In this study
we report the first application of isotope coded protein labeling
(ICPL), coupled with in-solution isoelectric fractionation and LC-MALDI-TOF/TOF,
to examine and prioritize urinary proteins from ovarian cancer patients.
Following the definition of stringent exclusion criteria a total of
579 proteins were identified with 43% providing quantitation data.
Protein abundance changes were validated for selected proteins by
ESI-Qq-TOF MS, following which Western blot and immunohistochemical
analysis by tissue microarray was used to explore the biological relevance
of the proteins identified. Several established markers (e.g., HE4,
osteopontin) were identified at increased levels in ovarian cancer
patient urine, validating the approach used; we also identified a
number of potential marker candidates (e.g., phosphatidylethanolamine
binding protein 1, cell-adhesion molecule 1) previously unreported
in the context of ovarian cancer. We conclude that the ICPL strategy
for identification and relative quantitation of urine proteins is
an appropriate tool for biomarker discovery studies, and can be applied
for the selection of potential biomarker candidates for further characterization
The utility of isotope-coded protein labeling for prioritization of proteins found in ovarian cancer patient urine
Urine offers a number of attractive features as a sample type for
biomarker discovery, including noninvasive sampling, quantity and
availability, stability, and a narrow dynamic range. In this study
we report the first application of isotope coded protein labeling
(ICPL), coupled with in-solution isoelectric fractionation and LC-MALDI-TOF/TOF,
to examine and prioritize urinary proteins from ovarian cancer patients.
Following the definition of stringent exclusion criteria a total of
579 proteins were identified with 43% providing quantitation data.
Protein abundance changes were validated for selected proteins by
ESI-Qq-TOF MS, following which Western blot and immunohistochemical
analysis by tissue microarray was used to explore the biological relevance
of the proteins identified. Several established markers (e.g., HE4,
osteopontin) were identified at increased levels in ovarian cancer
patient urine, validating the approach used; we also identified a
number of potential marker candidates (e.g., phosphatidylethanolamine
binding protein 1, cell-adhesion molecule 1) previously unreported
in the context of ovarian cancer. We conclude that the ICPL strategy
for identification and relative quantitation of urine proteins is
an appropriate tool for biomarker discovery studies, and can be applied
for the selection of potential biomarker candidates for further characterization
The utility of isotope-coded protein labeling for prioritization of proteins found in ovarian cancer patient urine
Urine offers a number of attractive features as a sample type for
biomarker discovery, including noninvasive sampling, quantity and
availability, stability, and a narrow dynamic range. In this study
we report the first application of isotope coded protein labeling
(ICPL), coupled with in-solution isoelectric fractionation and LC-MALDI-TOF/TOF,
to examine and prioritize urinary proteins from ovarian cancer patients.
Following the definition of stringent exclusion criteria a total of
579 proteins were identified with 43% providing quantitation data.
Protein abundance changes were validated for selected proteins by
ESI-Qq-TOF MS, following which Western blot and immunohistochemical
analysis by tissue microarray was used to explore the biological relevance
of the proteins identified. Several established markers (e.g., HE4,
osteopontin) were identified at increased levels in ovarian cancer
patient urine, validating the approach used; we also identified a
number of potential marker candidates (e.g., phosphatidylethanolamine
binding protein 1, cell-adhesion molecule 1) previously unreported
in the context of ovarian cancer. We conclude that the ICPL strategy
for identification and relative quantitation of urine proteins is
an appropriate tool for biomarker discovery studies, and can be applied
for the selection of potential biomarker candidates for further characterization
The utility of isotope-coded protein labeling for prioritization of proteins found in ovarian cancer patient urine
Urine offers a number of attractive features as a sample type for
biomarker discovery, including noninvasive sampling, quantity and
availability, stability, and a narrow dynamic range. In this study
we report the first application of isotope coded protein labeling
(ICPL), coupled with in-solution isoelectric fractionation and LC-MALDI-TOF/TOF,
to examine and prioritize urinary proteins from ovarian cancer patients.
Following the definition of stringent exclusion criteria a total of
579 proteins were identified with 43% providing quantitation data.
Protein abundance changes were validated for selected proteins by
ESI-Qq-TOF MS, following which Western blot and immunohistochemical
analysis by tissue microarray was used to explore the biological relevance
of the proteins identified. Several established markers (e.g., HE4,
osteopontin) were identified at increased levels in ovarian cancer
patient urine, validating the approach used; we also identified a
number of potential marker candidates (e.g., phosphatidylethanolamine
binding protein 1, cell-adhesion molecule 1) previously unreported
in the context of ovarian cancer. We conclude that the ICPL strategy
for identification and relative quantitation of urine proteins is
an appropriate tool for biomarker discovery studies, and can be applied
for the selection of potential biomarker candidates for further characterization
The utility of isotope-coded protein labeling for prioritization of proteins found in ovarian cancer patient urine
Urine offers a number of attractive features as a sample type for
biomarker discovery, including noninvasive sampling, quantity and
availability, stability, and a narrow dynamic range. In this study
we report the first application of isotope coded protein labeling
(ICPL), coupled with in-solution isoelectric fractionation and LC-MALDI-TOF/TOF,
to examine and prioritize urinary proteins from ovarian cancer patients.
Following the definition of stringent exclusion criteria a total of
579 proteins were identified with 43% providing quantitation data.
Protein abundance changes were validated for selected proteins by
ESI-Qq-TOF MS, following which Western blot and immunohistochemical
analysis by tissue microarray was used to explore the biological relevance
of the proteins identified. Several established markers (e.g., HE4,
osteopontin) were identified at increased levels in ovarian cancer
patient urine, validating the approach used; we also identified a
number of potential marker candidates (e.g., phosphatidylethanolamine
binding protein 1, cell-adhesion molecule 1) previously unreported
in the context of ovarian cancer. We conclude that the ICPL strategy
for identification and relative quantitation of urine proteins is
an appropriate tool for biomarker discovery studies, and can be applied
for the selection of potential biomarker candidates for further characterization
The utility of isotope-coded protein labeling for prioritization of proteins found in ovarian cancer patient urine
Urine offers a number of attractive features as a sample type for
biomarker discovery, including noninvasive sampling, quantity and
availability, stability, and a narrow dynamic range. In this study
we report the first application of isotope coded protein labeling
(ICPL), coupled with in-solution isoelectric fractionation and LC-MALDI-TOF/TOF,
to examine and prioritize urinary proteins from ovarian cancer patients.
Following the definition of stringent exclusion criteria a total of
579 proteins were identified with 43% providing quantitation data.
Protein abundance changes were validated for selected proteins by
ESI-Qq-TOF MS, following which Western blot and immunohistochemical
analysis by tissue microarray was used to explore the biological relevance
of the proteins identified. Several established markers (e.g., HE4,
osteopontin) were identified at increased levels in ovarian cancer
patient urine, validating the approach used; we also identified a
number of potential marker candidates (e.g., phosphatidylethanolamine
binding protein 1, cell-adhesion molecule 1) previously unreported
in the context of ovarian cancer. We conclude that the ICPL strategy
for identification and relative quantitation of urine proteins is
an appropriate tool for biomarker discovery studies, and can be applied
for the selection of potential biomarker candidates for further characterization
The utility of isotope-coded protein labeling for prioritization of proteins found in ovarian cancer patient urine
Urine offers a number of attractive features as a sample type for
biomarker discovery, including noninvasive sampling, quantity and
availability, stability, and a narrow dynamic range. In this study
we report the first application of isotope coded protein labeling
(ICPL), coupled with in-solution isoelectric fractionation and LC-MALDI-TOF/TOF,
to examine and prioritize urinary proteins from ovarian cancer patients.
Following the definition of stringent exclusion criteria a total of
579 proteins were identified with 43% providing quantitation data.
Protein abundance changes were validated for selected proteins by
ESI-Qq-TOF MS, following which Western blot and immunohistochemical
analysis by tissue microarray was used to explore the biological relevance
of the proteins identified. Several established markers (e.g., HE4,
osteopontin) were identified at increased levels in ovarian cancer
patient urine, validating the approach used; we also identified a
number of potential marker candidates (e.g., phosphatidylethanolamine
binding protein 1, cell-adhesion molecule 1) previously unreported
in the context of ovarian cancer. We conclude that the ICPL strategy
for identification and relative quantitation of urine proteins is
an appropriate tool for biomarker discovery studies, and can be applied
for the selection of potential biomarker candidates for further characterization